Dendreon Corporation (Nasdaq: DNDN) is a biotechnology company developing targeted therapies for cancer. The Company’s lead investigational product candidate, Provenge®, is a cancer immunotherapy undergoing Phase III clinical trials for the potential treatment of advanced-stage prostate cancer. In addition to its therapeutic vaccines in clinical and preclinical development for a variety of cancers, Dendreon’s product pipeline also includes monoclonal antibodies and a pathway to small molecules. Dendreon has established important research and development alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd.
People
Michelle Burris (CFO)
Terry Morris (Board Member)
Samuel Strober (Board Member)
Peter Garcia (CFO)
Gerardo Canet (Board Member)
News
Bellicum's prostate-cancer vaccine: Dendritic cells served with a genetic twist
October 12, 2007 9:52 pm
For a few brief months earlier this year, Dendreon‘s Provenge looked like it might become the first cancer vaccine approved… Continue reading ⟩
Life sciences briefing: Wednesday, Oct. 10, 2007
October 10, 2007 3:21 pm
Featured companies: 20/20 GeneSystems, Bellicum Pharmaceuticals, Cumbre Pharmaceuticals, Dara BioSciences, Enterprise Partners Venture Capital, Fermentas, International, Iasis Medical, New Leaf… Continue reading ⟩
Life sciences briefing: Friday, Sept. 21, 2007
September 21, 2007 2:43 pm
Featured companies: CG Therapeutics, Complete Genomics, ConforMIS, Flexible Medical Systems, LeMaitre Vascular, MAP Pharmaceuticals, ParaPro, Vascular Architects, Zars Pharma (UPDATED… Continue reading ⟩